Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR34 | Q9UPC5 | 3/20 | 0.49 |
| ▸ | CDK2 | P24941 | 6/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
| ▸ | YAP1 | P46937 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501081 | 1.00 | GPR34 (0.49) | GPR34CDK2PPARGPTPN1KCNA3 | |
| SCHEMBL3498501 | 0.94 | GPR34 (0.57) | GPR34PPARGPTPN1KCNA3 | |
| SCHEMBL3498497 | 0.94 | GPR34 (0.57) | GPR34PPARGPTPN1KCNA3 | |
| SCHEMBL3497391 | 0.88 | GPR34 (0.55) | GPR34CDK2PPARGPTPN1YAP1 | |
| SCHEMBL3497393 | 0.88 | GPR34 (0.55) | GPR34CDK2PPARGPTPN1YAP1 | |
| SCHEMBL3497029 | 0.88 | GPR34 (0.53) | GPR34CDK2PPARGPTPN1YAP1 | |
| SCHEMBL3497026 | 0.88 | GPR34 (0.53) | GPR34CDK2PPARGPTPN1YAP1 | |
| SCHEMBL3497396 | 0.86 | CDK2 (0.48) | GPR34CDK2PPARGPTPN1YAP1 | |
| SCHEMBL3497399 | 0.86 | CDK2 (0.48) | GPR34CDK2PPARGPTPN1YAP1 | |
| SCHEMBL3499956 | 0.86 | GPR34 (0.49) | GPR34CDK2PPARGPTPN1YAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | GPR34 1/4885CDK2 2075/4885PPARG 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.